Sign Up for Keystone Heart Updates
EU
US
Venus MedTech Partnership in China and Key Asian Markets
Keystone Heart and Venus MedTech Announce Partnership for Cerebral Embolic Protection with Transcatheter Heart Valve Systems (TAVR) in China and Key Asian Markets...
Read MorePress Releases
March 2, 2017
February 27, 2017
Keystone Heart Applauds FDA Advisory Panel for Recognition of The Need for Cerebral Protection Following TAVR
CAESAREA, Israel and TAMPA, Fla., Feb. 27, 2017 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral embolic protection...
Read More
February 27, 2017
Keystone Heart Applauds FDA Advisory Panel
Panel feedback echoes recently published NeuroARC research guidelines CAESAREA, Israel, and TAMPA, Florida — February 27, 2017— Keystone Heart...
Read More
November 1, 2016
Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR According to New Data Released at TCT 2016
According to New Data Released at TCT 2016 Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR CAESAREA,...
Read More
October 3, 2016
American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR
CAESAREA, Israel and TAMPA, Fla., Oct. 3, 2016 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for...
Read More
The Only CE Marked Cerebral Embolic Protection Device Designed to Cover all Three Major Aortic Vessels.
